“They would be happy if the owners would pay back the bonds. But in case they don’t, they know what to do.” Following successful investments in bonds from IDB, Matomy,

Brosh Capital is seeking to replace the Alcobra board of directors with its own directors. Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) today published a document stating that the Brosh Capital fund,

Company Adds Two Directors to the Board Company to Continue Strategic Alternatives Process to Maximize Value for All Shareholders TEL AVIV, Israel, June 12, 2017 (GLOBE NEWSWIRE) — Alcobra Ltd.

Kamada’s share price has plunged 40% in the past three months, following failure in a drug trial. Brosh Capital, led by portfolio manager and managing partner Amir Efrati, together with

Issues Open Letter to Chairman Outlining the Case for Change Expresses Concern with Alcobra’s Prolonged Underperformance, Capital Allocation, Board Oversight and Corporate Governance Nominates Six Highly Qualified Directors to Replace